Search the Newsreel

Summit Global Investments Buys Shares of 38,130 Interface, Inc. $TILE

Summit Global Investments has acquired 38,130 shares of Interface, Inc. (NASDAQ:TILE), valued at approximately $1.37 million, marking a new position for the institutional investor. Other large institutional investors also increased their holdings in Interface, which is currently 98.34% owned by institutions. Interface reported strong …

Local Pensions Partnership Investment Ltd Buys 4,000 Shares of Medpace Holdings, Inc. $MEDP

Local Pensions Partnership Investment Ltd increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5%, acquiring an additional 4,000 shares to bring its total to 42,000 shares valued at $22.3 million. Despite cautious analyst sentiment and significant insider selling, Medpace exceeded its quarterly earnings …

Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock

An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Howmet (HWM) Stock Could Look Overvalued As Raised Guidance Lands

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

ASTS Stock Crashes As Elaborate Satellite Launch Plans Fail To Outpower Earnings, Revenue Miss

SPCX Stock Suffers First Post-IPO Drop: Locked-Up Shares And Missing Shorts Skewed Debut Run, Analyst Says

Munich Reinsurance Co Stock Corp in Munich Has $53.62 Million Stake in Howmet Aerospace Inc. $HWM

Munich Reinsurance Co Stock Corp in Munich increased its stake in Howmet Aerospace Inc. (NYSE:HWM) by 2.1% in the second quarter, bringing its total holdings to 199,452 shares valued at approximately $53.62 million. Howmet Aerospace recently reported strong quarterly results with adjusted earnings of …

ASTS Stock Drops After Hours on Q2 Revenue Miss, Wider-Than-Expected Loss, Investor Focus On Future Launches

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Nvidia Stock Investors Just Got Good News From SpaceX. Wall Street Says It's Time to Buy.

Nvidia (NASDAQ: NVDA) is the cornerstone of the artificial intelligence infrastructure build-out. The company not only dominates the market for data center accelerators, with nearly 90% market share, but also has booming businesses in networking solutions and central processing units (CPUs). Nvidia shareholders recently …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

13,962 Shares in Extra Space Storage Inc $EXR Purchased by Dockside LLC

Dockside LLC recently acquired 13,962 shares of Extra Space Storage Inc (EXR) valued at approximately $2.03 million in the second quarter. This purchase contributes to the 99.11% institutional ownership of the company. Analysts have a mixed outlook with an average target price of $147.73, …

Firefly Aerospace (NASDAQ:FLY) Upgraded to Sell at Wall Street Zen

Wall Street Zen has upgraded Firefly Aerospace (NASDAQ:FLY) from a "strong sell" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus and an average price target of $36.82. The company reported a significant 659.2% year-over-year revenue increase to $117.68 million and …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Dynatrace (DT) Shares Moved, What Is Driving Attention Now?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Dynatrace (DT) is in focus after a series of August updates that combine earnings, fresh guidance, a completed buyback and leadership changes around …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

DT Stock Gains Over 4% — Dynatrace Draws Wall Street PT Hikes As AI Demand Fuels Bullish Calls

Rackspace Technology (NASDAQ:RXT) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Rackspace Technology (NASDAQ:RXT) to a "Sell" rating, aligning with a broader analyst consensus of "Reduce" and a target price of $4.00. The company recently reported a quarterly loss of $0.08 per share on revenue of $670.1 million, surpassing analyst estimates. …

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …